The Fink Family Office
VC Fund
The Fink Family Office is a VC fund focused on Biotechnology and Medical. The Fink Family Office operates as a family investment office.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries The Fink Family Office invests in
Stages The Fink Family Office invests in
Countries The Fink Family Office invests in
Investment Focus
Industry
- Biotechnology 3 (43%)
- Medical 2 (29%)
- Robotics 1 (14%)
- Biopharma 1 (14%)
- Electronics 1 (14%)
Stage
- Seed 4 (57%)
- Pre-Seed 1 (14%)
- Funding Round 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EnsiliTech
|
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M / Seed / Aug 28, 2025 | |
Argonaute RNA
|
Argonaute RNA is pursuing a number of therapeutic opportunities in RNA interference. RNAi harnesses a cell mechanism that inhibits the expression of a specific gene and thereby inhibits the production of a specific protein. Argonaute RNA research projects build on existing intellectual property. They show how their proprietary modification of smallinterfering RNA (siRNA) allows safe and effective ways to silence specific gene expression. | $2.3M / Jul 17, 2024 | |
MitoRx Therapeutics
|
MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. | $5M / Seed / Dec 13, 2023 | |
|
EnsiliTech
|
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $1.1M / Pre-Seed / Jan 17, 2023 | |
QV Bioelectronics
|
Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $2.4M / Seed / Jan 10, 2023 | |
cheMastery
|
CheMastery is a company that creates laboratory automation technology. They provide automation solutions for chemical laboratories in order to facilitate the manufacturing and R&D processes in the chemical sector. It makes science more effective and reliable for scientists in the chemical sector. | Seed / Nov 13, 2022 | |
|
MitoRx Therapeutics
|
MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. | Seed / Apr 25, 2022 |
Co-Investors
Empirical Ventures
10 deals together
Science Angel Syndicate
4 deals together
Elbow Beach Capital
3 deals together
Catapult Ventures
2 deals together
Hermesa
2 deals together
Longevitytech.fund
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does The Fink Family Office invest in?
The Fink Family Office invests primarily in Biotechnology, Medical and Robotics startups, most often at Seed and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did The Fink Family Office last invest?
The most recent investment recorded for The Fink Family Office closed in Aug 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
